RecruitingNCT00291096
High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast Cancer
Sponsor
Carol Fabian, MD
Enrollment
3,000 participants
Start Date
Aug 1, 1989
Study Type
OBSERVATIONAL
Conditions
Summary
The overall goal of this project is to develop an integrative system of breast cancer risk assessment based on epidemiologic and biologic risk variables, as well as to develop or refine risk biomarkers which may be useful in predicting and monitoring response to prevention interventions.
Eligibility
Sex: FEMALEMin Age: 30 YearsMax Age: 65 Years
Inclusion Criteria7
- women with at least 2 times the normal risk of developing breast cancer
- between the ages of 30-65 (or within 10 years of youngest age at diagnosis in first degree relative)
- greater than six months from ingestion of antihormonal therapy
- greater than 1 year from pregnancy, lactation, or chemotherapy
- willing to have a mammogram within six months prior to RPFNA
- willing to discontinue NSAIDS or herbal supplements
- willing to have blood drawn
Exclusion Criteria4
- no metastatic malignancy of any kind
- no breast implants or tram flap reconstructions
- no radiation to both breasts
- no women who have a current mammogram or clinical breast exam suspicious for cancer
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT00291096
Related Trials
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT0661828763 locations
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
NCT069260753 locations
EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients
NCT074780161 location
Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System
NCT052915071 location
Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia
NCT0693085934 locations